Bcal Diagnostics Ltd (bdx) Logo

Bcal Diagnostics Ltd (BDX)

___:___ · Healthcare

BDX Chart


BDX's Principal Activity is the bCAL Diagnostics Limited is a biotechnology company developing a blood based diagnostic test for breast cancer.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -60.97%


Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,939 of 2,413
Sector Rank 176 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies NC6 / GLH / RGS
EPS $0.00
DPS $0.00
Book Value Per Share $0.00

Broker Consensus

BDX is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

BCAL Diagnostics Limited (BDX) s a company focused on the development of a non-invasive blood based in vitro diagnostic (IVD) technology to detect breast cancer.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Sydney NSW 2000
Website www.bcaldiagnostics.com
Registry Automic Group
Auditor Pitcher Partners Sydney
Date Listed 21 Jul 2021

Upcoming Calendar (Forecasted)

Date Event
30/08/2022 Report (Prelim)
27/09/2022 Report (Annual)
17/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr John Hurrell Chief Executive Officer Feb 2022
Mr Mark Douglas Irving Burrows Non-Executive Director Jul 2021

Mr Mark Douglas Irving Burrows

Non-Executive Director

Mr Burrows has experience in diagnosis of breast cancer and other cancers. He has career in investment banking both in Australia and the UK. Mark co-founded Baring Brothers Burrows & Co in Australia in the early 80s. In 1999 he was appointed the Managing Director/ Deputy Chairman of ING Barings in London. In 2004, Mark joined Lazard as a Managing Partner and in 2006 returned to Australia and was appointed Lazard Australia's inaugural Chairman. Mark returned to investment banking in 2011 as Vice Chairman of Credit Suisse's Global Investment Bank. During his investment banking career, Mark has been the principal financial advisor to some of the transformative corporate and government transactions in Australia. Mark has served as a non-executive director on several Australasian and UK public companies including Chairman and Deputy Chair of Brambles, Fairfax Media and Telstra. Since the Rio Earth Summit in 1992, Mark has also been supporter of global financial institutions' Private Sector involvement in sustainable development. Over this period, Mark has retained a number of roles advising United Nations, G20 and corporates on climate initiatives relating to the financial sector. From 2017 to 2020, Mark was a Senior Advisor to Macquarie Bank, on climate finance and renewable energy. Mark currently retains a role as a senior advisor to UNEP, UNDP, The Green Finance Initiative in London and is on the Asian Council of The Nature Conservancy. He is also a Senior Advisor to the G20 Sustainability Group.

Dr Merilyn Joy Sleigh Non-Executive Director Mar 2021

Dr Merilyn Joy Sleigh

Non-Executive Director

Dr Sleigh has over 30 years of experience as a senior executive and non-executive director in Australia's biotechnology sector. She was, from its foundation, Chief Executive Officer and Managing Director of EvoGenix Limited, a biotech startup company that expanded internationally and listed on the ASX before acquisition by a larger company. She was formerly Dean of the Faculty of Life Sciences, University of NSW; Director of Research & Development at Australian biotech Peptech Ltd and a research scientist and senior manager with CSIRO. She has held non-executive director positions with Mimetica Pty Ltd and Adalta Ltd as well as with ASX listed companies Clover Corporation, and Tyrian Diagnostics Ltd. Other director roles have been with government and not-for-profit organisations, including the Rural Industries Research and Development Corporation and Relationships Australia. She has acted as an adviser and consultant to companies, government, research institutes and investors on technology commercialization. She is also member of the Risk Management Committee of BDX.

Mr Jonathan Alfred Grey Trollip Non-Executive Director Dec 2020

Mr Jonathan Alfred Grey Trollip

Non-Executive Director

Mr Trollip is an experienced Director with over 30 years of commercial, corporate, governance and legal and transactional experience. He is currently non-executive Chairman of ASX listed Global Value Fund Limited, Future Generation Investment Company Limited, Antipodes Global Investment Company Limited, Plato Income Maximser Limited, and Spheria Emerging Companies Limited and a non-executive director of ASX listed Propel Funeral Partners Limited and LSE listed Kore Potash PLC. He has experience in the not-for-profit sector. He is also chairman of the Risk Management Committee of BDX.

Ms Jayne Andrea Shaw Executive Chairman,Executive Director Feb 2010

Ms Jayne Andrea Shaw

Executive Chairman,Executive Director

Ms Shaw has become a Director of Nursing and Chief Executive Officer of two private hospitals in Australia after completion of her training in nursing. Following this, she established an Australian and international consulting business which was sold to Healthsouth, a USA Healthcare company. Jayne then became the Co-founder of Vision Group, an Ophthalmic Doctor equity consolidation model that was successfully listed on the ASX. Jayne joined a number of private healthcare boards involved with specialist consolidation including Cardiology, Orthopaedics, and Women's Health, and continued to work with private equity firms on local and international healthcare transactions. Jayne, together with Ron Phillips, was a co-owner of Sydney Breast Clinic and a co-founder of BCAL. Current board positions are The Woolcock Research Institute, Corum Group (ASX: COO) and Mable Technologies.

Hon Ronald (Ron) Anthony Phillips Non-Executive Director Feb 2010

Hon Ronald (Ron) Anthony Phillips

Non-Executive Director

The Hon Phillips has been worked for 15 years in the NSW Parliament which included serving as Minister for Health and Deputy Leader of the Opposition. Ron has developed a consulting business in the Health and Aged Care Industry. His business interests included co-owner and Managing Director of Sydney Breast Clinic which he sold to Healthscope. He recently retired as Chair of the Sydney Local Health District and as Director of Westmead IVF. He is also member of the Risk Management Committee of BDX.

Mr Guy Adrian Robertson Chief Financial Officer,Company Secretary N/A
John Hurrell Chief Executive Officer N/A

Director Transactions

BDX directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
01/03/22 Merilyn Sleigh Buy +80,000 $0.11 $8,800 On-market trade
09/12/21 Jayne Shaw Buy +357,143 $0.14 $50,000 On-market trade
09/12/21 Mark Burrows Buy +357,142 $0.14 $50,000 On-market trade
07/09/21 Jayne Shaw Buy +20,000 $0.20 $4,002 On-market trade
06/09/21 Jayne Shaw Buy +180,000 $0.20 $36,000 On-market trade

Director Interests

The current holdings of BDX directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Merilyn Sleigh 01/03/2022 80,000 N/A N/A N/A
Jayne Shaw 09/12/2021 N/A 28,126,745 2,022,638 N/A
Mark Burrows 09/12/2021 N/A 800,050 N/A N/A
Jonathan Trollip 23/12/2020 N/A 3,147,649 1,155,793 N/A
Ronald (Ron) Phillips 15/02/2010 8,102,858 18,411,709 2,022,638 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Jul 14, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Nabelle Pty Ltd (The Shaw Super Fund A/C) 19,162,405 9.26%
The Trust Company (Australia) Limited (MOF A/C) 17,420,171 8.42%
Ann Marie Phillips 16,574,988 8.01%
Mera Vale No 3 Pty Ltd (Mera Vale No 3 A/C) 12,943,471 6.26%
Ronald Anthony Phillips 8,102,858 3.92%
Regal Funds Management 7,971,945 3.85%
Coolbrun Pty Ltd 6,633,789 3.21%
Nabelle Pty Ltd (The Shaw Family A/C) 5,815,172 2.81%
Carwoola Pastoral Co Pty Ltd 4,424,895 2.14%
CS Third Nominees Pty Limited (HSBC Cust Nom Au Ltd 13 A/C) 4,000,000 1.93%
Barrijag Pty Ltd (Hadley Family A/C) 3,890,741 1.88%
Bizcapital Pty Limited 3,562,205 1.72%
Angelo Korsanos & Antonia Korsanos (Korsanos Family A/C) 3,484,050 1.68%
Vintage Dawn Pty Ltd (Jamie & Caroline Odell S/F) 3,484,050 1.68%
Sean Kennedy 3,300,303 1.60%
Peter French 3,259,408 1.58%
Piaster Pty Ltd (Trollip Family S/F A/C) 3,147,649 1.52%
Darville Pty Limited 3,101,660 1.50%
Scapa Pty Ltd 3,048,563 1.47%
Peter Alan Murray 2,819,558 1.36%
UBS Nominees Pty Ltd 2,725,000 1.32%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 0 3 157 150 127 437

Substantial Shareholders

No Substantial Shareholders for BDX in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
19-01-22 Capital Property Corporation Pty Ltd 10,750,302 -- 5.20
21-07-21 Regal Funds Management Pty Limited 12,171,945 -- 5.88

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
22-10-21 Regal Funds Management Pty Limited 12,171,945 5.88 --

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
BDX Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.